| Entry |
|
|---|
| Name |
Tivozanib (USAN/INN) |
|---|
| Formula |
C22H19ClN4O5
|
|---|
| Exact mass |
454.1044
|
|---|
| Mol weight |
454.86
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03203 VEGFR inhibitor
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG01375): | D10190<US> |
|
|---|
| Efficacy |
Antineoplastic, Angiogenesis inhibitor, Receptor tyrosine kinase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01EK03 Tivozanib
D09683 Tivozanib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03203 VEGFR inhibitor
DG01375 Tivozanib
D09683 Tivozanib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01375 Tivozanib
D09683 Tivozanib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
VEGFR family
VEGFR1 (FLT1)
D09683 Tivozanib (USAN/INN)
VEGFR2 (KDR)
D09683 Tivozanib (USAN/INN)
VEGFR3 (FLT4)
D09683 Tivozanib (USAN/INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09683
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03203 VEGFR inhibitor
DG01375 Tivozanib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01375 Tivozanib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 32
1 C8y C 12.8800 -20.3000
2 C8y C 12.8800 -21.7000
3 C8x C 14.0924 -22.4000
4 C8y C 15.3049 -21.7000
5 C8y C 15.3049 -20.3000
6 C8x C 14.0924 -19.6000
7 C8y C 16.5173 -22.4000
8 C8x C 17.7297 -21.7000
9 C8x C 17.7297 -20.3000
10 N5x N 16.5173 -19.6000
11 O2a O 16.5173 -23.8000
12 C8y C 17.7318 -24.5012
13 O2a O 11.6676 -19.6000
14 C1a C 10.4721 -20.2904
15 O2a O 11.6676 -22.4000
16 C1a C 10.4721 -21.7096
17 C8x C 17.7318 -25.8998
18 C8y C 18.9442 -26.5999
19 C8y C 20.1566 -25.8999
20 C8x C 20.1567 -24.5012
21 C8x C 18.9442 -23.8012
22 N1b N 21.3716 -26.6014
23 C5a C 22.5683 -25.9103
24 N1b N 23.7550 -26.5955
25 C8y C 24.9466 -25.9073
26 O5a O 22.5685 -24.5003
27 X Cl 18.9442 -27.9998
28 C8x C 24.9467 -24.5003
29 N5x N 26.2848 -26.3422
30 O2x O 27.1119 -25.2038
31 C8y C 26.2849 -24.0655
32 C1a C 26.7094 -22.7575
BOND 35
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 7 11 1
13 11 12 1
14 1 13 1
15 13 14 1
16 2 15 1
17 15 16 1
18 12 17 2
19 17 18 1
20 18 19 2
21 19 20 1
22 20 21 2
23 12 21 1
24 19 22 1
25 22 23 1
26 23 24 1
27 24 25 1
28 23 26 2
29 18 27 1
30 25 28 1
31 25 29 2
32 29 30 1
33 30 31 1
34 28 31 2
35 31 32 1
|
|---|
